UCM in the AFR, page-24

When the non-holders come & downramp, I know im on a winner!

UCM is now:
- Cash flow positive & cash balance was +500k in the quarter to date
- Chinese Coronavirus Treatment Recommendations formally endorse the use of USCOM 1A
- Chinese sales booming
- US Salesforce geared up
- EU approval imminent

Outside of all this:
- There are 7 additional products in their approval pipeline for FDA & NMPA approval, all of which expected in the next 6 months (as per their last annual report presso)

So we have a global med-tech company which is past the development phase of their lifecycle as they're now cash flow positive and have an additional tailwind of 7 new products in development which are expecting approval within 6 mths.

Further to this, their lead product - USCOM 1A - is being recommended by the Chinese Government for the treatment of Covid_19 in their hospitals.

This story sells itself & the readers in the AFR this morning absolutely understand this!

It's not uncommon for med-techs with global reach on the Aussie mkt to command valuations approaching $1B after the development phase (i.e. in cash flow positive phase)

UCM finds itself in this predicament with a mkt cap of sub 50m ... for the time being